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Abstract
Background: Studies describing venous thromboembolic event (VTEE) and atrial fibrillation (AF) in South American
populations are limited. The aim of this cross-sectional study was to describe the characteristics of Venezuelan
patients admitted and treated for these conditions.
Methods: A retrospective medical record review of 1397 consecutive patients admitted to three private hospitals
or clinics between January 2000 and December 2005 was performed. Data was collected on demographics,
anthropometrics, hospital visit, comorbidities and treatment.
Results: Among 401 VTEE and 996 AF patients, men were more likely to have AF (58%) while more women
experienced a VTEE (58%). Most patients were admitted via the emergency room (87%) and had only one event
during the study period (83%). Common comorbidities included hypertension (46%), heart failure (17%), diabetes
(12%) and congestive heart failure (11%). Characteristics of Venezuelan patients with VTEE and AF are similar to that
reported in the literature for other populations.
Conclusions: These results provide background characteristics for future studies assessing risk factors for AF and
VTEE in South American populations.
Background
The size of the elderly population is growing rapidly
worldwide, including developed and developing coun-
tries [1]. Older age is a risk factor for developing many
diseases, including venous thromboembolic events
(VTEE) and atrial fibrillation (AF). Thus, the disease
burden associated with VTEE and AF is expected to
expand as elderly populations continue to rise.
The impact of VTEE and AF on mortality and mor-
bidity is substantial, as are the socioeconomic conse-
quences in terms of hospital admissions and
management of chronic diseases and disabilities. AF is
the most common cardiac rhythm disorder, affecting
approximately 2.3 million people in the United States
(US) and 4.8 million in the 6 major pharmaceutical mar-
kets (France, Spain, Germany, United Kingdom, Italy,
Japan,) combined [2]. VTEEs are common vascular
diseases with an average annual incidence rate among in
the US and Europe of 100 to 200 per 100,000 person-
years in the US and Europe; roughly 900,000 incident or
recurrent cases occurring annually in the US alone
[3-6]. The incidence rate appears to be similar or higher
among African-Americans and lower for Asian- and
Native-American populations in the US [7,8].
Although the epidemiology of VTEE and AF is very
well described in North America and Europe, there is a
paucity of published epidemiological data on the
descriptive epidemiology of patients with these condi-
tions in South American populations. Therefore, we
conducted a descriptive study of patients diagnosed with
VTEE and AF to better understand the disease burden
in Venezuela.
Methods
Using a retrospective cross-sectional study design, we
reviewed medical records for two groups of adult (18+
years) patients (VTEE or AF) diagnosed between January
2000 and December 2005 at three private Venezuelan
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hospitals or clinics located in Caracas: Clínica Santa
Sofía, Policlínica Metropolitana, and Hospital de Clínicas
Caracas. Hospital de Clinicas Caracas, the most technolo-
gically advanced private health care institution in Vene-
zuela with 13,500 admissions, 7,000 annual surgeries and
180 beds for inpatient population. The hospital provides
primary, tertiary, and transplant services and employs
400 physicians and 373 nurses who provide excellent
medical care services. Policlinica Metropolitana and Clin-
ica Santa Sofia are another 2 private clinics that provide
excellent medical services. Both clinics provide primary,
tertiary and transplant services as well. All hospitals and
clinics included in the study maintain a central repository
of electronic medical records for all patients admitted
through the emergency rooms. The diagnosis of VTEE or
AF was defined using the International Classification of
Disease 10th Revision (ICD- 10) and confirmed by the
treating physician [9]. This research received a waiver of
consent from the Independent Ethics Committee ("Comi-
sión de Bioética y Bioseguridad del Fondo Nacional de
Ciencia y Tecnología”) in Venezuela for use of patient
medical record data.
Data was abstracted from medical records using a
structured case report form to gather information regard-
ing age, gender, weight, source at index hospitalization,
admission diagnosis, use of anticoagulation therapy,
length of hospital stay and disposition, comorbidities
(defined by ICD-10 codes) and medications (Venezuela’s
Vademecum). Vademecum is a medication handbook
which contains information on trademarks, active princi-
ples, interactions, adverse reactions, international equiva-
lences, and manufacturers. Descriptive statistics were
calculated using SPSS V. 12 software.
Results
The study population included 401 patients with VTEEs
and 996 AF patients (Table 1). The most common
VTEEs were phlebitis or thrombophlebitis (67%), pul-
monary embolism (17%), other venous embolism or
thrombosis (9%), venous embolism combined with phle-
bitis (6%). The mean age at diagnosis was 60.1 and 70.7
years old for VTEE and AF patients, respectively. More
VTEEs occurred among women (58%), whereas AF was
more common in men (58%). Most patients presented
at the emergency room (VTEE: 89%, AF: 87%) with
mean hospitalization duration of approximately 5 days
for both patient groups. The majority of patients experi-
enced a single VTEE (88%) or AF (80%) event during
the study period from 2000 to 2005. Most patients
returned home following hospitalization; 5 VTEE and 4
AF patients readmitted to the hospital (data not shown).
Comorbidities were generally more common among AF
patients compared to patients diagnosed with a VTEE.
Hypertension was the most common comorbidity
observed in both VTEE (26%) and AF (54%) patients,
followed by heart failure (VTEE: 3%, AF: 23%), diabetes
(VTEE: 12%, AF: 12%) and congestive heart failure
(VTEE: 3%, AF: 14%). Cancer more common among
VTEE patients (8%) compared with AF patients (4%). In
a subset of patients with anthropometric data available,
mean height and weight were similar in both disease
groups (data not shown).
Table 2 describes the primary hospital admission and
discharge codes for the VTEE and AF patients. Deep
vein thromboembolism was the most common hospital
admission (41%) and discharge (53%) diagnosis for
VTEE patients. Among AF patients, AF was listed as the
admission diagnosis for only 44% of population; how-
ever, AF was recorded as the primary diagnosis for 86%
of patients at the time of hospital discharge.
As presented in Table 3, enoxaparin and warfarin
were the mostly commonly prescribed anticoagulant
medications for both VTEE and AF, although a larger
proportion of VTEE patients (66% and 68%, respec-
tively) were prescribed these medications compared to
Table 1 Characteristics of patients diagnosed with a






Age (years), mean (range) 60.1 (22-103) 70.7 (18-101)
Sex, N (%)
Male 168 (42%) 577 (58%)
Female 230 (58%) 410 (42%)
No. VTEE/AF Events, 2000- 2005, N
(%)
1 354 (88%) 798 (80%)
2 37 (9%) 146 (15%)
3 8 (2%) 35 (3%)
4+ 2 (<1%) 17 (2%)
Hospital Admission Source, N (%)
Emergency room 356 (89%) 865 (87%)
Routine admission/outpatient 27 (7%) 76 (8%)
Transfer 16 (4%) 51 (5%)
Unknown 2 (<1%) 4 (<1%)
Days of Hospital Stay, mean (range) 5.4 (1-75) 4.5 (1-49)
Comorbidities, N (%)
Hypertension 105 (26%) 540 (54%)
Heart failure 13 (3%) 225 (23%)
Diabetes 46 (12%) 122 (12%)
Congestive heart failure 12 (3%) 134 (14%)
Cancer 33 (8%) 35 (4%)
Coronary artery disease 4 (1%) 47 (5%)
Prior myocardial infarction 2 (<1%) 45 (5%)
Prior transient ischemic attack 2 (<1%) 37 (4%)
Prior stroke 4 (1%) 29 (3%)
Prior bleeding event 0 2 (<1%)
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AF patients (48% and 32%). Heparin was used more fre-
quently among VTEE patients (40%) compared to those
with AF (3%); roughly 3% of both patient groups were
treated with dalteparin. The most common concomitant
medications among the VTEE patients were proton-
pump inhibitors (38%), H2 blockers (33%), and benzo-
diazepines (30%). A similar proportion of AF patients
were treated with these same medications, but the
majority was also treated with antiarrhythmic drugs
(83%). Twenty (2%) of AF patients and 3 (<1%) of VTEE
patients died during the study period (data not shown).
Discussion
This is one of the first studies describing the epidemiol-
ogy of VTEE and AF in Venezuela. The frequency of
some common and rare comorbid conditions in the
Venezuelan patient population is similar to what has
been observed in North American and European popu-
lations. For example, approximately one quarter of
VTEE and half of all AF patients in the Venezuelan
population were hypertensive; similar rates have been
reported in the literature [10-14]. Rare events such as
prior myocardial infarction, transient ischemic attack or
stroke each occurred in roughly 0-5% of AF patients in
the present study as well as other large cohorts
[11,12,14]. The prevalence of heart failure and diabetes
found in Venezuelan VTEE and AF populations also is
similar to what has been reported in other published stu-
dies [10-15]. This new research suggests that Venezuelan
patients with VTEE and AF share similar epidemiologic
characteristics and risk factors for developing these con-
ditions as populations in other parts of the world.
We found that the Venezuelan VTEE population was
less likely to have cancer as a comorbidity (8%) com-
pared to VTEE patients in the US and Europe which
ranges from 20-32% [10,15,16]. It is estimated that can-
cer accounts for approximately 20% of incident VTEE in
the US and the risk is highest for patients diagnosed
with certain types of cancer or receiving particular
therapies such as immunosuppressive or cytotoxic che-
motherapy [3]. It is possible that the lower cancer
Table 2 Common hospital admission and discharge
diagnoses for patients with venous thromboembolic





n % n %
Admission diagnosis
Atrial fibrillation 0 0.0% 439 44.1%
Deep venous thromboembolism 165 41.1% 0 0.0%
Cerebrovascular accident 6 1.5% 86 8.6%
Cardiac insufficiency 8 2.0% 60 6.0%
Pulmonary embolism 45 11.2% 0 0.0%
Thrombophlebitis 34 8.5% 0 0.0%
Ischemic cardiopathy 3 0.7% 27 2.7%
Pneumonia 6 1.5% 21 2.1%
Unstable angina 0 0.0% 27 2.7%
Respiratory infection 4 1.0% 23 2.3%
Hypertension 5 1.2% 22 2.2%
Respiratory insufficiency 12 3.0% 14 1.4%
Cellulitis 25 6.2% 0 0.0%
Embolism/thromb. of arteries lower
extrem.
21 5.2% 0 0.0%
Arrhythmia 0 0.0% 14 1.4%
Syncope 0 0.0% 14 1.4%
Pulmonary oedema 0 0.0% 12 1.2%
Acute coronary syndrome 1 0.2% 11 1.1%
Other 66 16.5% 226 22.7%
Discharge diagnosis
Atrial fibrillation 0 0.0% 857 86.0%
Deep venous thromboembolism 212 52.9% 3 0.3%
Pulmonary embolism 64 16.0% 7 0.7%
Thrombophlebitis 47 11.7% 0 0.0%
Cardiac insufficiency 6 1.5% 38 3.8%
Cerebrovascular accident 4 1.0% 24 2.4%
Venous embolism and thrombosis 23 5.7% 1 0.1%
Ischemic cardiopathy 5 1.2% 14 1.4%
Auricular flutter 0 0.0% 14 1.4%
Other 40 10.0% 39 3.9%
Table 3 Common medications prescribed for patients






n % n %
Anticoagulant used
Dalteparin sodium 12 3.0% 24 2.4%
Enoxaparin 264 65.8% 476 47.8%
Heparin sodium 159 39.7% 32 3.2%
Warfarin sodium 271 67.6% 323 32.4%
Class of Concomitant Medications
Antiarrhythmic drugs 38 9.5% 831 83.4%
Proton-pump inhibitors 151 37.7% 293 29.4%
Benzodiazepines 119 29.7% 312 31.3%
H2 blockers 131 32.7% 239 24.0%
Diuretics 22 5.5% 248 24.9%
Antiplatelet drugs 51 12.7% 188 18.9%
Angiotensin-converting enzyme inhibitor 27 6.7% 208 20.9%
Beta blockers 25 6.2% 156 15.7%
Aldosterone receptor antagonists 15 3.7% 141 14.2%
Nonsteroidal anti-inflammatory
medications
66 16.5% 73 7.3%
Salicylates 17 4.2% 85 8.5%
Quinolone antibiotics 31 7.7% 54 5.4%
Calcium antagonist 9 2.2% 71 7.1%
Cephalosporins 44 11.0% 26 2.6%
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prevalence in Venezuelans with VTEE is explained by
reduced access to expensive or experimental cancer
treatments or differences in incidence rates of cancers
such as digestive malignancies that are more closely
associated with VTEE [3,17].
There are several strengths to this cross-sectional
study. First, the retrospective study included the use of
ICD-10 diagnosis codes and Vademecum medication
codes which provide consistent patient data. The use of
ICD codes has been shown to reliably capture cardiovas-
cular and cerebrovascular events [18,19]. For example,
defining patient-level covariates by the ICD-10 diagnoses
are quite good and coded with high sensitivity for cor-
onary artery disease/ischemic heart disease (98%), dia-
betes mellitus (99%), history of cerebrovascular accident
(95%), hypertension (83%), and TIA (79%) [20,21].
Further, we studied data from the major private hospi-
tals or clinics serving the Caracas population.
This study has several limitations. As with most stu-
dies based on medical record data, this study was lim-
ited by the information recorded in the physicians’
notes. We did not validate the data about the sensitivity
or specificity of the ICD-10 codes used to identify VTEE
or AF patients. Additionally, no other standard clinical
criteria or definitions beyond ICD-10 codes were used
to define the VTEE or AF events. Thus, the complete-
ness of the captured VTEE or AF events is unclear.
However, the ICD-10 classification system includes dis-
tinct codes for the diseases of interest, reducing the like-
lihood of misclassification. Previous studies have
reported high sensitivity associated with ICD-10 dis-
charge codes for PE (89%) and AF (98%); the sensitivity
for DVT diagnoses is lower (58%) [22,20]. It is unclear
whether the patients from the three hospitals and clinics
are representative of the overall population in Vene-
zuela. For example, these clinics may represent a higher
socioeconomic bracket than the average for Venezuela.
This study does not include an internal comparison
group to determine whether the characteristics of VTEE
or AF patients significantly differ from the general
population.
Little is known about VTEE or AF in regions outside
the United States or Europe. This study provides a start-
ing point for additional future analyses of these diseases
in South American populations. Accurately assessing the
region-specific disease burden, patient characteristics
and treatment patterns is essential for understanding
the unmet needs and improving public health.
Conclusions
In conclusion, the study provides evidence that Vene-
zuelan patients diagnosed with VTEE and AF events are
similar with regard to epidemiological and clinical fac-
tors as North American and European patients.
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